A Phase 2, Open-Label, Randomized Two-part, Multiple Dose Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic Hepatitis B Virus

Trial Profile

A Phase 2, Open-Label, Randomized Two-part, Multiple Dose Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic Hepatitis B Virus

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs SB 9200 (Primary) ; Tenofovir disoproxil fumarate
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Acronyms ACHIEVE
  • Sponsors Spring Bank Pharmaceuticals
  • Most Recent Events

    • 06 Oct 2017 According to a Spring Bank Pharmaceuticals media release, data from this trial will be presented at the annual American Association for the Study of Liver Disease (AASLD) conference (The Liver Meeting) 2017
    • 28 Aug 2017 According to a Spring Bank Pharmaceuticals media release, additional data from the first cohort of patients will be presented at the 2017 International HBV Meeting on the Molecular Biology of Hepatitis B Viruses.
    • 31 Jul 2017 According to a Spring Bank Pharmaceuticals media release, the company plans to report top-line results from the second monotherapy dosing cohort of this trial in 4Q 2017. Top-line results from the first cohort of patients in this trial have been disclosed and patient enrollment in the second cohort of this trial has been completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top